Fibroblast cell therapy enhances initial healing in recessive dystrophic epidermolysis bullosa wounds: Results of a randomized, vehicle-controlled trial

British Journal of Dermatology

Volumn 169, Issue 5, 2013, Pages 1025-1033

  Petrof, G ^a   Martinez Queipo, M ^a   Mellerio, J E ^a   Kemp, P ^b   McGrath, J A ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b Intercytex Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ALLOTRANSPLANTATION; ARTICLE; CELL THERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EPIDERMOLYSIS BULLOSA DYSTROPHICA; EROSION; ERYTHEMA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; INJECTION SITE PAIN; MALE; NEWBORN; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA; SKIN FIBROBLAST; SKIN INJURY; TREATMENT OUTCOME; WOUND ASSESSMENT; WOUND CARE; WOUND CLOSURE; WOUND HEALING;

ADOLESCENT; ADULT; AGED; CELL- AND TISSUE-BASED THERAPY; DOUBLE-BLIND METHOD; EPIDERMOLYSIS BULLOSA DYSTROPHICA; FEMALE; FIBROBLASTS; HUMANS; INJECTIONS, INTRADERMAL; MALE; MIDDLE AGED; PHARMACEUTICAL VEHICLES; PROSPECTIVE STUDIES; QUALITY OF LIFE; TREATMENT OUTCOME; WOUND HEALING; YOUNG ADULT;

EID: 84887040998     PISSN: 00070963     EISSN: 13652133     Source Type: Journal    
DOI: 10.1111/bjd.12599     Document Type: Article

References (20)

1. Fine JD, Eady RA, Bauer EA, et al,. The classification of inherited epidermolysis bullosa (EB): report of the Third International Consensus Meeting on Diagnosis and Classification of EB. J Am Acad Dermatol 2008; 58: 931-50.
2. Hilal L, Rochat A, Duquesnoy P, et al,. A homozygous insertion-deletion in the type VII collagen gene (COL7A1) in Hallopeau-Siemens dystrophic epidermolysis bullosa. Nat Genet 1993; 5: 287-93.
3. Stanley JR, Rubinstein N, Klaus-Kovtun V,. Epidermolysis bullosa acquisita antigen is synthesized by both human keratinocytes and human dermal fibroblasts. J Invest Dermatol 1985; 85: 542-5.
4. Fine JD, Mellerio JE,. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part I. Epithelial associated tissues. J Am Acad Dermatol 2009; 61: 367-84.
5. Fine JD, Mellerio JE,. Extracutaneous manifestations and complications of inherited epidermolysis bullosa: part II. Other organs. J Am Acad Dermatol 2009; 61: 387-402.
6. Bruckner-Tuderman L, McGrath JA, Robinson EC, et al,. Progress in epidermolysis bullosa research: summary of DEBRA International Research Conference 2012. J Invest Dermatol 2013; 133: 2121-6.
7. Wong T, Gammon L, Liu L, et al,. Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa. J Invest Dermatol 2008; 128: 2179-89.
8. El Ghalbzouri A, Ponec M,. Diffusible factors released by fibroblasts support epidermal morphogenesis and deposition of basement membrane components. Wound Repair Regen 2004; 12: 359-67.
9. Ortiz-Urda S, Lin Q, Green CL, et al,. Injection of genetically engineered fibroblasts corrects regenerated human epidermolysis bullosa skin tissue. J Clin Invest 2003; 111: 251-5.
10. Woodley DT, Krueger GG, Jorgensen CM, et al,. Normal and gene-corrected dystrophic epidermolysis bullosa fibroblasts alone can produce type VII collagen at the basement membrane zone. J Invest Dermatol 2003; 121: 1021-8.
11. Nagy N, Almaani N, Tanaka A, et al,. HB-EGF induces COL7A1 expression in keratinocytes and fibroblasts: possible mechanism underlying allogeneic fibroblast therapy in recessive dystrophic epidermolysis Bullosa. J Invest Dermatol 2011; 131: 1771-4.
12. European Medicines Agency. Committee for Medicinal Products for Human Use. Guidelines on Clinical Trials in Small Populations. CHMP/EWP/83561/2005. London: EMA, 2006. Available at: http://www.ema.europa.eu/docs/en-GB/document- library/Scientific-guideline/2009/09/WC500003615.pdf (last accessed 27 September 2013).
13. Venugopal SS, Yan H, Tran K, et al,. Investigation of cell therapy for generalized severe recessive dystrophic epidermolysis bullosa by intradermal allogeneic fibroblasts randomized against placebo injections. Australas J Dermatol 2009; 50: A56 [abstr].
14. Kirsner RS, Marston WA, Snyder RJ, et al,. Spray-applied cell therapy with human allogeneic fibroblasts and keratinocytes for the treatment of chronic venous leg ulcers: a phase 2, multicentre, double-blind, randomised, placebo-controlled trial. Lancet 2012; 380: 977-85.
15. McGrath JA, Schofield OM, Ishida-Yamamoto A, et al,. Cultured keratinocyte allografts and wound healing in severe recessive dystrophic epidermolysis bullosa. J Am Acad Dermatol 1993; 29: 407-19.
16. Falabella AF, Valencia IC, Eaglstein WH, et al,. Tissue-engineered skin (Apligraf) in the healing of patients with epidermolysis bullosa wounds. Arch Dermatol 2000; 136: 1225-30.
17. Fivenson DP, Scherschun L, Choucair M, et al,. Graftskin therapy in epidermolysis bullosa. J Am Acad Dermatol 2003; 48: 886-92.
18. Natsuga K, Sawamura D, Goto M, et al,. Response of intractable skin ulcers in recessive dystrophic epidermolysis bullosa patients to an allogeneic cultured dermal substitute. Acta Derm Venereol 2010; 90: 165-9.
19. Conget P, Rodriguez F, Kramer S, et al,. Replenishment of type VII collagen and re-epithelialization of chronically ulcerated skin after intradermal administration of allogeneic mesenchymal stromal cells in two patients with recessive dystrophic epidermolysis bullosa. Cytotherapy 2010; 12: 429-31.
20. Wagner JE, Ishida-Yamamoto A, McGrath JA, et al,. Bone marrow transplantation for recessive dystrophic epidermolysis bullosa. N Engl J Med 2010; 363: 629-39.